SM-102

Description

JenKem Technology provides high purity SM-102, Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxO-6-(undecyloxy) hexyl) amino) octanoate), CAS no: 2089251-47-6, for Lipid Nanoparticles and mRNA delivery (sample for research purpose only, not for sale).

LNP drug delivery systems are commonly employed for nucleic acid delivery. LNPs are generally believed to combine with the cell membrane through noncovalent affinity and absorbed by endocytosis. After being absorbed by the cell, the mRNA delivered by LNPs are released to the cytoplasm and express the target protein, escaping from the endocytosis. This technology has been adopted by pharmaceutical companies in the recent years for COVID-19 vaccine manufacture¹.

Please visit https://www.jenkemusa.com/products-for-lnps-and-rna-delivery to learn about our PEG and small molecule product line for LNPs and mRNA delivery. Please contact us at sales@jenkemusa.com to inquire about the availability of samples of SM-102, Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxO-6-(undecyloxy) hexyl) amino) octanoate), CAS no: 2089251-47-6.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high-quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified and adheres to ICH Q7 guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.

References:

1. Schoenmaker, Linde, et al., mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability, International Journal of Pharmaceutics 601 (2021)